Amorphous Drug Formulation

Modern drug discovery tools have biased towards compounds with poor aqueous solubility even though the importance of drug-like properties has long been recognized [1], and the trend continues to deteriorate [2]. The poor solubility of these drug candidates imposes great challenges to pharmaceutical scientists and engineers who are ultimately responsible for developing a bioavailable drug product to support the clinical programs and commercialization, if successful. A poorly water soluble drug candidate not only may lengthen the formulation development phase, increase the resource demands, delay the clinical trials due to insufficient in vivo exposure, but also may impact the ultimate success of the entire program due to suboptimal bioavailability [3].